Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Dr. James McCaffrey presents a complete end-to-end demonstration of linear regression with pseudo-inverse training implemented using JavaScript. Compared to other training techniques, such as ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...

Isomorphic Labs has raised $600m in its first external funding round as it pushes forward with artificial intelligence (AI)-driven drug discovery. Thrive Capital led the financing round, with ...

Brian Beers is a digital editor, writer, Emmy-nominated producer, and content expert with 15+ years of experience writing about corporate finance & accounting, fundamental analysis, and investing.

Google DeepMind, the artificial intelligence company behind the popular AlphaFold tool, has published the next generation of the application’s protein structure prediction software. The new tool can ...

Enzymes help with specific functions that are vital to the operation and overall health of the human body. They help speed up chemical reactions and are essential for respiration, digestion, muscle ...

Andrew Bloomenthal has 20+ years of editorial experience as a financial journalist and as a financial services marketing writer. Samantha (Sam) Silberstein, CFP®, CSLP®, EA, is an experienced ...